Aural
- Address
- 45 Rue Du Docteur Leon Mangeney, 68100 Mulhouse, France
Cardiovascular Diseases
The research at Aural focuses on cardiovascular disease in patients with severe kidney impairment, aiming to test new anticoagulant strategies that may lower heart attacks, strokes and related events.
- Low-dose anticoagulation for advanced chronic kidney disease
- Safety comparison of novel oral anticoagulants versus traditional therapy
- Preventing major cardiovascular events in dialysis-dependent patients
With three investigators overseeing two trials, the site seeks to improve heart health outcomes for those undergoing dialysis.
Reproductive and Urinary Physiological Phenomena
Studies target end-stage renal disease and peritoneal dialysis patients who also have non‑valvular atrial fibrillation, evaluating how blood‑thinning medicines affect bleeding and overall safety.
- Optimizing treatment for dialysis patients with atrial fibrillation
- Assessing bleeding risk of anticoagulants in renal failure
- Enhancing quality of life for individuals on chronic peritoneal dialysis
The work at Aural in Mulhouse contributes to better management of kidney‑related cardiovascular complications across Europe.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Aural
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Comparative Safety and Efficacy of Apixaban Versus Warfarin in Patients with End-Stage Renal Disease on Peritoneal Dialysis and Non-Valvular Atrial Fibrillation | Centre Hospitalier Universitaire De Caen Normandie | Phase III | Recruiting | Jan 2025 | — |
IMP list
lock Showing 1 of 4 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Apixaban | 1 | Unknown | 2025-01-08 | 2025-01-08 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.